Login to Your Account



Medco kicks off critical pivotal inclisiran program

By Michael Fitzhugh
Staff Writer

Monday, November 6, 2017

Patient dosing has begun in the first of four pivotal trials key to The Medicines Co.'s big bet on inclisiran, a cardiovascular-focused RNAi therapy critical to the drugmaker's return to profitability.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription